<div id="readability-page-1"><p>Hsbc Holdings PLC trimmed its position in shares of  Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.1% in the second quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 189,237 shares of the company's stock after selling 53,798 shares during the period. Hsbc Holdings PLC owned 0.19% of Neurocrine Biosciences worth $23,787,000 at the end of the most recent quarter.</p><ul><li>3 Biotech Stocks to Watch: Iovance, Neurocrine &amp; Viking</li></ul><p>Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Cetera Investment Advisers raised its holdings in shares of  Neurocrine Biosciences by 45.1% during the first quarter. Cetera Investment Advisers now owns 11,857 shares of the company's stock valued at $1,311,000 after buying an additional 3,688 shares during the last quarter.  Jefferies Financial Group Inc. bought a new position in  Neurocrine Biosciences in the 1st quarter worth approximately $498,000.  Raiffeisen Bank International AG increased its position in  Neurocrine Biosciences by 42.6% in the 1st quarter. Raiffeisen Bank International AG now owns 16,258 shares of the company's stock valued at $1,839,000 after acquiring an additional 4,858 shares during the period.  ASR Vermogensbeheer N.V. bought a new stake in  Neurocrine Biosciences during the 1st quarter valued at $465,000.  Finally, Charles Schwab Investment Management Inc. boosted its position in  Neurocrine Biosciences by 1.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 775,773 shares of the company's stock worth $85,800,000 after acquiring an additional 13,216 shares during the period. Institutional investors own  92.59% of the company's stock. </p><div><p><span></span><span>Get <strong>Neurocrine Biosciences</strong> alerts:</span></p></div><h2>Neurocrine Biosciences Trading Down 0.8%</h2><p>Shares of Neurocrine Biosciences stock opened at $150.88 on Tuesday. The company's 50-day moving average price is $142.96 and its two-hundred day moving average price is $135.26. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $157.67. The stock has a market cap of $15.04 billion, a PE ratio of 36.10, a price-to-earnings-growth ratio of 0.94 and a beta of 0.22. </p><ul><li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li></ul><p>Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.59. The company had revenue of $794.90 million during the quarter, compared to analyst estimates of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The business's revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.81 EPS.  On average, equities analysts predict that  Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research analysts have recently issued reports on NBIX shares. UBS Group increased their price target on Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, October 9th. Stifel Nicolaus increased their target price on shares of Neurocrine Biosciences from $174.00 to $183.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. Royal Bank Of Canada raised their target price on shares of Neurocrine Biosciences from $156.00 to $160.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, October 29th. Weiss Ratings  restated a &#34;hold (c+)&#34; rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. Finally, Morgan Stanley reduced their price target on shares of Neurocrine Biosciences from $178.00 to $173.00 and set an &#34;overweight&#34; rating for the company in a research note on Tuesday, November 11th. One investment analyst  has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $170.53.</p><ul><li>Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?</li></ul><p><b>View Our Latest Research Report on Neurocrine Biosciences</b></p><h2>Insider Buying and Selling</h2><p>In other Neurocrine Biosciences news, Director George J. Morrow sold 15,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total value of $2,150,550.00. Following the transaction, the director owned 7,068 shares in the company, valued at approximately $1,013,339.16. The trade was a 67.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William H. Rastetter sold 18,000 shares of Neurocrine Biosciences stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the transaction, the director owned 40,360 shares in the company, valued at $6,127,455.20. The trade was a 30.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 33,300 shares of company stock worth $4,925,901. Corporate insiders own  4.80% of the company's stock. </p><h2>Neurocrine Biosciences Profile</h2> (Free Report)<p>Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Neurocrine Biosciences</li><li>How is Compound Interest Calculated?</li><li>Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>Congress Beat the Market Again—Here Are the 3 Stocks They Bought</li><li>Using the MarketBeat Dividend Tax Calculator</li><li>Go on a Shopping Spree With 3 Top Retail ETFs</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Neurocrine Biosciences Right Now?</h2><p>Before you consider Neurocrine Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.</p><p>While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

00005

HSBC

NBIX

<p>HSBC Holdings PLC reduced its stake in Neurocrine Biosciences, Inc. by 22.1% in Q2, selling 53,798 shares, now holding 189,237 shares valued at $23.79 million. Neurocrine's Q3 earnings beat estimates with $2.17 EPS and $794.90 million revenue. Analysts rate the stock as a "Moderate Buy" with a $170.53 average price target. Director George J. Morrow sold 15,000 shares, reducing his ownership by 67.97%.</p>

- Hsbc Holdings PLC reduced its stake in Neurocrine Biosciences by 22.1%, owning 189,237 shares valued at $23.79 million after selling 53,798 shares.  
- The company reported a quarterly earnings per share of $2.17, exceeding estimates, with revenue of $794.90 million, a 27.8% year-over-year increase.  
- Analysts maintain a "Moderate Buy" rating for Neurocrine, with an average price target of $170.53, while institutional investors hold 92.59% of the stock.

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hsbc Holdings PLC